Efficacy and quality of antibacterial generic products approved for human use: A systematic review

Clinical Infectious Diseases

Volumn 58, Issue 4, 2014, Pages 458-469

  Tattevin, Pierre ^a,b   Crémieux, Anne Claude ^c,d   Rabaud, Christian ^e   Gauzit, Rémy ^f  

^a Department of Pediatric Oncology   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d RAYMOND POINCARÉ HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

^f HÔTEL DIEU   (France)

Author keywords

antibacterial agents; bactericidal activity; drug regulatory agency; generics; pharmacokinetic

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN PLUS PROBENECID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFPODOXIME; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; COTRIMOXAZOLE; GENERIC DRUG; GENTAMICIN; GLYCOPEPTIDE; MEROPENEM; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CHEMISTRY; CLINICAL EFFECTIVENESS; CLINICAL STUDY; DRUG EFFICACY; DRUG PURITY; DRUG QUALITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICATION COMPLIANCE; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; STUDY DESIGN; SYSTEMATIC REVIEW; TASTE; ANIMAL; BACTERIAL INFECTIONS; CHEMICAL ANALYSIS; DISEASE MODEL; MICROBIAL SENSITIVITY TEST;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHEMISTRY TECHNIQUES, ANALYTICAL; DISEASE MODELS, ANIMAL; DRUGS, GENERIC; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84893222137     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit769     Document Type: Article

References (40)

1. Garcia-Arieta A, Gordon J. Bioequivalence requirements in the European Union: critical discussion. AAPS J 2012; 14:738-48.
2. Gauzit R, Lakdhari M. Generic antibiotic drugs: is effectiveness guaranteed? Med Mal Infect 2012; 42:141-8.
3. Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 2008; 71:525-30.
4. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008; 300:2514-26.
5. Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother 2010; 54:3271-9.
6. Rodriguez CA, Agudelo M, Zuluaga AF, Vesga O. Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model. Antimicrob Agents Chemother 2012; 56:243-7.
7. Medscape-France. Antibiotiques generiques et princeps: sont-ils vraiment equivalents? [Antibiotic generics and innovators: are they really equivalent]. 2011. Available at: http://www.tmedscape.fr/infections-vaccins/articles/1279851/ . Accessed 29 November 2013.
8. Rodriguez CA, Agudelo M, Zuluaga AF, Vesga O. In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin. BMC Infect Dis 2010; 10:153.
9. Del Tacca M, Pasqualetti G, Di Paolo A, et al. Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers. Br J Clin Pharmacol 2009; 68:34-42.
10. Wu H, Liu M, Wang S, et al. Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, openlabel, two-period crossover study in healthy Chinese male volunteers. Clin Ther 2010; 32:597-606.
11. Jones RN, Fritsche TR, Moet GJ. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation. Diagn Microbiol Infect Dis 2008; 61:76-9.
12. Moet GJ,Watters AA, Sader HS, Jones RN. Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots. Diagn Microbiol Infect Dis 2009; 65:319-22.
13. Silva E, Diaz JA, Arias MJ, Hernandez AP, de la Torre A. Comparative in vitro study of the antimicrobial activities of different commercial antibiotic products for intravenous administration. BMC Clin Pharmacol 2010; 10:3.
14. Tschudin-Sutter S, Frei R, Widmer AF. Equal efficacy of a generic piperacillin/tazobactam formulation: results of a local screening protocol. Diagn Microbiol Infect Dis 2011; 69:286-7.
15. Lambert PA, Conway BR. Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin. J Chemother 2003; 15:357-68.
16. Schito GC, Keenan MH. Predicting the clinical efficacy of generic formulations of ceftriaxone. J Chemother 2005; 17(suppl 2):33-40.
17. Mastoraki E, Michalopoulos A, Kriaras I, et al. Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime. J Infect 2008; 56:35-9.
18. Cohen R, de La Rocque F, Lecuyer A, Wollner C, Bodin MJ,Wollner A. Study of the acceptability of antibiotic syrups, suspensions, and oral solutions prescribed to pediatric outpatients. Eur J Pediatr 2009; 168:851-7.
19. Wollner A, Lecuyer A, De La Rocque F, et al. Acceptability, compliance and schedule of administration of oral antibiotics in outpatient children [in French]. Arch Pediatr 2011. [Epub ahead of print].
20. Tansuphasawadikul S, Simaroj S, Chantarothorn S, et al. Therapeutic effectiveness of a generic versus original meropenem in serious infections. J Med Assoc Thai 2011; 94:172-8.
21. Angkasekwinai N, Werarak P, Chaiyasoot K, Thamlikitkul V. Monitoring of effectiveness and safety of generic formulation of meropenem for treatment of infections at Siriraj Hospital. J Med Assoc Thai 2011; 94(suppl 1):S217-24.
22. Piyasirisilp S, Premprawat W, Thamlikitkul V. Therapeutic equivalence of generic imipenem/cilastatin for therapy of infections at Siriraj hospital. J Med Assoc Thai 2010; 93(suppl 1):S117-25.
23. Fujimura S, Watanabe A, Fuse K, Kikuchi T, Gomi K, Tokue Y. In vitro susceptibility of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) to manufactured generic drugs compared with the brand vancomycin. Int J Antimicrob Agents 2008; 31:391-2.
24. Fujimura S, Fuse K, Takane H, et al. Antibacterial effects of brandname teicoplanin and generic products against clinical isolates of methicillin-resistant Staphylococcus aureus. J Infect Chemother 2011; 17: 30-3.
25. Rodriguez CA, Agudelo M, Catano JC, Zuluaga AF, Vesga O. Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia. J Infect 2009; 59:277-80.
26. Diaz JA, Silva E, Arias MJ, Garzon M. Comparative in vitro study of the antimicrobial activities of different commercial antibiotic products of vancomycin. BMC Clin Pharmacol 2011; 11:9.
27. Conte JE Jr. Comparative antibacterial activity of Vancocin and generic vancomycin. Antimicrob Agents Chemother 1987; 31:333-4.
28. Nambiar S, Madurawe RD, Zuk S, et al. Product quality of parenteral vancomycin products in the United States. Antimicrob Agents Chemother 2012; 56:2819-23.
29. Hadwiger ME, Sommers CD, Mans DJ, Patel V, Boyne MT 2nd. Quality assessment of US marketplace vancomycin for injection products using high resolution LC-MS and potency assays. Antimicrob Agents Chemother 2012; 56:2824-30.
30. Tattevin P, Saleh-Mghir A, Davido B, et al. Comparison of six generic vancomycin products for the treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits. Antimicrob Agents Chemother 2012; 57:1157-62.
31. Zuluaga AF, Agudelo M, Cardeno JJ, Rodriguez CA, Vesga O. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model. PLoS One 2010; 5: e10744.
32. Jensen US, Muller A, Brandt CT, Frimodt-Moller N, Hammerum AM, Monnet DL. Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance. J Antimicrob Chemother 2010; 65:1286-91.
33. Nightingale CH. A survey of the quality of generic clarithromycin products from 18 countries. Clin Drug Investig 2005; 25:135-52.
34. Snyman JR, Schoeman HS, Grobusch MP, et al. Generic versus nongeneric formulation of extended-release clarithromycin in patients with community-acquired respiratory tract infections: a prospective, randomized, comparative, investigator-blind, multicentre study. Clin Drug Investig 2009; 29:265-74.
35. Boonleang J, Panrat K, Tantana C, Krittathanmakul S, Jintapakorn W. Bioavailability and pharmacokinetic comparison between generic and branded azithromycin capsule: a randomized, double-blind, 2-way crossover in healthy male Thai volunteers. Clin Ther 2007; 29:703-10.
36. Najib NM, Idkaidek N, Ghanem IE, et al. Bioequivalence assessment of azomycin (Julphar, UAE) as compared to Zithromax (Pfizer, USA)-two brands of azithromycin-in healthy human volunteers. Biopharm Drug Dispos 2001; 22:15-21.
37. Gulati R, Tripathi CD, Chandra D. Comparative bioavailability of two formulations of azithromycin. J Assoc Physicians India 2000; 48:606-8.
38. Pineyro-Lopez A, Pineyro-Garza E, Torres-Alanis O, et al. Bioavailability of two oral formulations of azithromycin 500 mg: a randomized, open-label, two-period crossover comparison in healthy Mexican adult subjects. Clin Ther 2005; 27:1607-11.
39. Agudelo M, Vesga O. Therapeutic equivalence requires pharmaceutical, pharmacokinetic, and pharmacodynamic identities: true bioequivalence of a generic product of intravenous metronidazole. Antimicrob Agents Chemother 2012; 56:2659-65.
40. El-Chaar GM, Mardy G,Wehlou K, Rubin LG. Randomized, double blind comparison of brand and generic antibiotic suspensions: II. A study of taste and compliance in children. Pediatr Infect Dis J 1996; 15:18-22.